This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.

Back to overview

Alfred Schinkel group


Alfred Schinkel

Group leader

Personal details


Alfred Schinkel received his Bachelor's degree in biology/biochemistry (1979) and his Master's degree in biochemistry (1983, cum laude) from the University of Amsterdam, The Netherlands. He obtained a Ph.D. in molecular biology in 1989 (cum laude) from the University of Amsterdam as well.

From 1988 to 1996 he completed postdoctoral fellowships at the Netherlands Cancer Institute, and then worked during 1996/1997 as a visiting scientist at the National Cancer Institute of the National Institutes of Health in Bethesda, Maryland, U.S.A.

From 1997 he worked as a group leader at the Netherlands Cancer Institute in Amsterdam, obtaining tenure in 2002. He received the Dutch Galenus Prize 1993 for work on P-glycoprotein and its role in the blood-brain barrier, and the Antoni van Leeuwenhoek Prize 1994 for his research on the biological role of P-glycoproteins involved in multidrug resistance.

Current research interests include the physiological, pharmacological, and toxicological roles of multidrug efflux and uptake transporters, and of multidrug metabolizing enzymes. Techniques used include generation and characterization of knockout and transgenic mouse strains for these multidrug detoxifying proteins, and development and utilization of in vitro models to study these systems. The insights and tools obtained allow optimization of the development of new drugs and drug administration regimens, in order to maximize therapeutic efficacy and minimize toxicity of drug therapy. Over 150 primary research papers have been published since 1983, resulting in an h-index >70 (as of 2013).

Share this page